Canadian liver journal · 2025
Trends in hepatitis C care in Canada's provincial and territorial prisons from 2020 to 2024.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Albaini Obey, Laprise Frederique, Anderson-Apopei Jennifer, Bartlett Sofia, Brown Ashley, Goralczyk Kayley, Kaita Kelly, Kiefer Lori, Levesque Janelle, Martin Brandi, Meloche Audrey, Myrah Danielle, Nakehk'o Rielle, Slaunwhite Amanda, Whitten Cindy, Kronfli Nadine
Аннотация
BACKGROUND: National hepatitis C virus (HCV) elimination efforts are contingent on the provision of care in prisons. This study aimed to assess HCV care practices in Canada's provincial/territorial prisons in 2024, comparing trends from 2020 to 2024.
METHODS: From June 14 to October 31, 2024, one representative per prison health care team (excluding Nunavut) completed a web-based survey. The outcomes of interest were HCV screening, access to direct-acting antivirals (DAAs), linkage to care following release, and access to opioid agonist therapies (OAT) and prison-based needle and syringe programs (PNSPs). Non-nominal data were aggregated by province, and descriptive statistical analyses were used to report outcomes.
RESULTS: The survey was completed by 88/94 (94%) prisons. In total, 85 prisons offered HCV screening. On-demand (15/85; 18%), risk-based (1/85; 1%), and opt-in (9/85; 11%) screening declined since 2020, while opt-out (15/85; 18%) and combination (45/85; 53%) screening increased. Reflex RNA testing occurred in over half (46/85; 54%) of prisons. DAAs were offered in 74/88 (84%) prisons, and 65/74 (88%) provided the remainder of DAAs at release to facilitate treatment completion. In 2024, the majority (78/88; 89%) of prisons facilitated continuity of care following release. OAT was available in most prisons (83/88; 94%), and in 2024, more prisons offered OAT for people who had never been on OAT (73/83; 88%). Not a single prison had implemented PNSPs.
CONCLUSIONS: While there were improvements in prison-based HCV care from 2020 to 2024, HCV care was still not equivalent to that in the community in 2024, jeopardizing HCV elimination efforts both in prisons and in surrounding communities.
METHODS: From June 14 to October 31, 2024, one representative per prison health care team (excluding Nunavut) completed a web-based survey. The outcomes of interest were HCV screening, access to direct-acting antivirals (DAAs), linkage to care following release, and access to opioid agonist therapies (OAT) and prison-based needle and syringe programs (PNSPs). Non-nominal data were aggregated by province, and descriptive statistical analyses were used to report outcomes.
RESULTS: The survey was completed by 88/94 (94%) prisons. In total, 85 prisons offered HCV screening. On-demand (15/85; 18%), risk-based (1/85; 1%), and opt-in (9/85; 11%) screening declined since 2020, while opt-out (15/85; 18%) and combination (45/85; 53%) screening increased. Reflex RNA testing occurred in over half (46/85; 54%) of prisons. DAAs were offered in 74/88 (84%) prisons, and 65/74 (88%) provided the remainder of DAAs at release to facilitate treatment completion. In 2024, the majority (78/88; 89%) of prisons facilitated continuity of care following release. OAT was available in most prisons (83/88; 94%), and in 2024, more prisons offered OAT for people who had never been on OAT (73/83; 88%). Not a single prison had implemented PNSPs.
CONCLUSIONS: While there were improvements in prison-based HCV care from 2020 to 2024, HCV care was still not equivalent to that in the community in 2024, jeopardizing HCV elimination efforts both in prisons and in surrounding communities.